159 related articles for article (PubMed ID: 2553248)
1. Altered formation of DNA in human cells treated with inhibitors of DNA topoisomerase II (etoposide and teniposide).
Lönn U; Lönn S; Nylen U; Winblad G
Cancer Res; 1989 Nov; 49(22):6202-7. PubMed ID: 2553248
[TBL] [Abstract][Full Text] [Related]
2. Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization.
Gewirtz DA; Ellis AL; Randolph JK; Yanovich S; Swerdlow PS; Povirk LF; Yalowich JC
Cancer Commun; 1989; 1(3):175-80. PubMed ID: 2561738
[TBL] [Abstract][Full Text] [Related]
3. Protein-linked DNA strand breaks produced by etoposide and teniposide in mouse L1210 and human VA-13 and HT-29 cell lines: relationship to cytotoxicity.
Kerrigan D; Pommier Y; Kohn KW
NCI Monogr; 1987; (4):117-21. PubMed ID: 3041238
[TBL] [Abstract][Full Text] [Related]
4. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
5. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
7. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
Qiu J; Catapano CV; Fernandes DJ
Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of resistance to DNA topoisomerase II inhibitors].
Kohno K; Takano H; Kuwano M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1568-73. PubMed ID: 1651684
[TBL] [Abstract][Full Text] [Related]
9. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
10. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition.
Chow KC; Macdonald TL; Ross WE
Mol Pharmacol; 1988 Oct; 34(4):467-73. PubMed ID: 2845248
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
12. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
Yang L; Rowe TC; Liu LF
Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
14. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
[TBL] [Abstract][Full Text] [Related]
15. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
16. Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells.
Tan KB; Mattern MR; Boyce RA; Hertzberg RP; Schein PS
NCI Monogr; 1987; (4):95-8. PubMed ID: 2819739
[TBL] [Abstract][Full Text] [Related]
17. Studies of topoisomerase-specific antitumor drugs in human lymphocytes using rabbit antisera against recombinant human topoisomerase II polypeptide.
Hwang JL; Shyy SH; Chen AY; Juan CC; Whang-Peng J
Cancer Res; 1989 Feb; 49(4):958-62. PubMed ID: 2536295
[TBL] [Abstract][Full Text] [Related]
18. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.
Kaufmann SH
Cancer Res; 1989 Nov; 49(21):5870-8. PubMed ID: 2790800
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of topoisomerase II by ICRF-193 does not support a role for topoisomerase II activity in the fragmentation of chromatin during apoptosis of human leukemia cells.
Beere HM; Chresta CM; Hickman JA
Mol Pharmacol; 1996 May; 49(5):842-51. PubMed ID: 8622634
[TBL] [Abstract][Full Text] [Related]
20. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Long BH; Musial ST; Brattain MG
Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
